TITLE 77: PUBLIC HEALTH
CHAPTER I: DEPARTMENT OF PUBLIC HEALTH
SUBCHAPTER u: MISCELLANEOUS PROGRAMS AND SERVICES
PART 946 COMPASSIONATE USE OF MEDICAL CANNABIS PATIENT REGISTRY
SECTION 946.35 MEDICAL CANNABIS ADVISORY BOARD
Section 946.35 Medical Cannabis Advisory Board
a) The Department shall convene a Medical Cannabis Advisory Board (Advisory Board) composed of 16 members, including (Section 45(q) of the Act):
1) One medical cannabis patient advocate or designated caregiver;
2) One parent or designated caregiver of a person under age 18 who is a qualified medical cannabis patient;
3) Two registered nurses or nurse practitioners;
4) Three registered qualifying patients, including one veteran; and
5) Nine health care practitioners with current professional licensure in their field. The Advisory Board shall be composed of health care practitioners representing the following areas:
B) Pain management;
C) Medical oncology;
D) Psychiatry or mental health;
E) Infectious disease;
F) Family medicine;
G) General primary care;
H) Medical ethics;
J) Pediatrics; or
K) Psychiatry or mental health for children or adolescents.
At least one appointed health care practitioner shall have direct experience related to the health care needs of veterans and at least one individual shall have pediatric experience.
b) Members of the Advisory Board shall be appointed by the Governor.
1) Members shall serve a term of four years or until a successor is appointed and qualified. If a vacancy occurs, the Governor shall appoint a replacement to complete the original term created by the vacancy.
2) The Governor shall select a chairperson.
3) Members may serve multiple terms.
4) Members shall not have an affiliation with, serve on the board of, or have a business relationship with a registered cultivation center or a registered medical cannabis dispensary.
5) Members shall disclose any real or apparent conflicts of interest that may have a direct bearing of the subject matter, such as relationships with pharmaceutical companies, biomedical device manufacturers, or corporations whose products or services are related to the medical condition or disease to be reviewed.
6) Members shall not be paid but will be reimbursed for travel expenses incurred while fulfilling the responsibilities of the Advisory Board.
c) The Advisory Board shall convene at the call of the Chair to:
1) Examine debilitating conditions or diseases that would benefit from the medical use of cannabis, and;
2) Review any new medical and scientific evidence pertaining to currently approved debilitating conditions.
3) The Advisory Board shall issue an annual report of its activities each year.
(Source: Added at 40 Ill. Reg. 16753, effective December 15, 2016)